Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


No Safety Shortcuts Under Breakthrough Designation, Synthetic Biologics Finds

Executive Summary

Synthetic Biologics emerged from meetings with US FDA without its breakthrough designation, but with hope that agency will allow decoupling of safety and efficacy endpoints in planned Phase III trial for prevention of C. difficile infection.

Related Content

Keeping Track: CDER Approves Its First Two Novel Agents Of 2019
Synthetic Biologics’ Ribaxamase Setback Shows Difficulty Of C. Difficile Development
Expedited Review Pathways: Three More Breakthroughs, Third RMAT Awarded
Harvoni Approval Led To Narrowing Of Epclusa's Breakthrough Status
Bye, Bye ‘Breakthrough’: Bristol, Merck HCV Drugs Face Loss Of Special Designation
Industry, FDA Face Changes In Handling Of Missing Clinical Trial Data


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts